ALK-Abello’s Pharmalgen Wins U.K. Cost-Agency Backing for Stings
Stock Chart for ALK-Abello A/S (ALKB)
ALK-Abello A/S’s Pharmalgen won the preliminary backing of the U.K.’s health-cost agency for the treatment of severe reactions to bee and wasp stings.
As many as nine people die every year in the U.K. from allergic reactions, known as anaphylaxis, to the stings, the National Institute for Health and Clinical Excellence said in an e-mailed statement. Pharmalgen, an injection, prevents the reaction by desensitizing the immune system, said the agency, known as NICE.
A final decision probably will be made by February, NICE said. ALK-Abello is based in Hoersholm, Denmark.
To contact the reporter responsible for this story: Phil Serafino in Paris at email@example.com
To contact the editor responsible for this story: Phil Serafino at firstname.lastname@example.org
Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.